1. MAPK/ERK Pathway
  2. MEK
  3. Mirdametinib

Mirdametinib  (Synonyms: PD0325901; PD325901)

製品番号: HY-10254G
取扱説明書 Technical Support

Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Mirdametinib

Mirdametinib 構造式

CAS 番号 : 391210-10-9

容量 価格(税別) 在庫状況 数量
10 mg $1320 在庫あり
50 mg $4200 在庫あり
100 mg $6400 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

MEK アイソフォーム固有の製品をすべて表示:

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor[1][2][3].

Cellular Effect
Cell Line Type Value Description References
A-375 GI50
1.28 nM
Compound: 5; PD-325901
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay
[PMID: 36924668]
A-375 GI50
1.37 nM
Compound: 5; PD-325901
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 1 min and measured 72 hrs post compound treatment by CellTiter-Glo lumi
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 1 min and measured 72 hrs post compound treatment by CellTiter-Glo lumi
[PMID: 36924668]
A-375 GI50
1.49 nM
Compound: 5; PD-325901
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum
[PMID: 36924668]
A-375 GI50
1.59 nM
Compound: 5; PD-325901
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 3 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum
Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 3 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum
[PMID: 36924668]
A-375 IC50
13 nM
Compound: PD325901
Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay
Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay
[PMID: 23474388]
A-431 IC50
<0.014 μM
Compound: PD-0325901
Inhibition of MEK/ERK signaling pathway in TNFalpha-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with TNFalpha for 10 mins by Western blot analysis
Inhibition of MEK/ERK signaling pathway in TNFalpha-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with TNFalpha for 10 mins by Western blot analysis
[PMID: 27502541]
A-431 IC50
0.038 μM
Compound: PD-0325901
Inhibition of MEK/ERK signaling pathway in EGF-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with EGF for 10 mins by Western blot analysis
Inhibition of MEK/ERK signaling pathway in EGF-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with EGF for 10 mins by Western blot analysis
[PMID: 27502541]
A549 CC50
>100 μM
Compound: PD-0325901
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
[PMID: 33539089]
A549 GI50
10.6 nM
Compound: 5; PD-325901
Antiproliferative activity against human A549 cells harboring KRas G13S mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lumin
Antiproliferative activity against human A549 cells harboring KRas G13S mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lumin
[PMID: 36924668]
A549 GI50
4.94 nM
Compound: 5; PD-325901
Antiproliferative activity against human A549 cells harboring KRAS G13S mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay
Antiproliferative activity against human A549 cells harboring KRAS G13S mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay
[PMID: 36924668]
A549 IC50
0.06 μM
Compound: PD0325901
Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
[PMID: 32305784]
A549 IC50
166 nM
Compound: PD325901
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
[PMID: 23474388]
A549 IC50
166 nM
Compound: PD325901
Antiproliferative activity against human A549 cells harboring K-Ras mutation
Antiproliferative activity against human A549 cells harboring K-Ras mutation
[PMID: 26611920]
COLO 205 GI50
0.2 nM
Compound: 4; PD0325901
Antiproliferative activity against human COLO205 cells assessed as reduction in cell growth after 3 days by WST8 assay
Antiproliferative activity against human COLO205 cells assessed as reduction in cell growth after 3 days by WST8 assay
[PMID: 31730343]
COLO 205 IC50
5 nM
Compound: PD325901
Antiproliferative activity against human COLO205 cells harboring BRAF mutation
Antiproliferative activity against human COLO205 cells harboring BRAF mutation
[PMID: 26611920]
HCT-116 GI50
44.7 nM
Compound: 5; PD-325901
Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay
Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay
[PMID: 36924668]
HCT-116 GI50
52.5 nM
Compound: 5; PD-325901
Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lu
Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lu
[PMID: 36924668]
HCT-116 IC50
0.09 μM
Compound: PD0325901
Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
[PMID: 32305784]
HCT-116 IC50
185 nM
Compound: PD325901
Antiproliferative activity against human HCT116 cells harboring K-Ras G13D mutation
Antiproliferative activity against human HCT116 cells harboring K-Ras G13D mutation
[PMID: 26611920]
HCT-116 IC50
194 nM
Compound: PD325901
Antiproliferative activity against human HCT116 cells expressing KRAS G13D mutant
Antiproliferative activity against human HCT116 cells expressing KRAS G13D mutant
[PMID: 23474388]
HEK-293T GI50
>10000 nM
Compound: 5; PD-325901
Cytotoxicity against HEK293T cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter-Glo luminescent assay
Cytotoxicity against HEK293T cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter-Glo luminescent assay
[PMID: 36924668]
HEK-293T GI50
>10 μM
Compound: 5; PD-325901
Cytotoxicity against HEK293T cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter-Glo luminescent assay
Cytotoxicity against HEK293T cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter-Glo luminescent assay
[PMID: 36924668]
HepG2 IC50
5 nM
Compound: PD325901
Antiproliferative activity against human HepG2 cells harboring N-Ras mutation
Antiproliferative activity against human HepG2 cells harboring N-Ras mutation
[PMID: 26611920]
HL-60 IC50
0.0013 μM
Compound: PD0325901
Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
[PMID: 32305784]
HT-29 GI50
3.1 nM
Compound: 4; PD0325901
Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay
[PMID: 31730343]
LoVo IC50
128 nM
Compound: PD325901
Antiproliferative activity against human LoVo cells
Antiproliferative activity against human LoVo cells
[PMID: 23474388]
MCF7 IC50
9550 nM
Compound: PD325901
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
[PMID: 26611920]
MDA-MB-231 GI50
1 μM
Compound: PD-0325901
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
[PMID: 30802730]
MDA-MB-231 IC50
0.082 μM
Compound: PD0325901
Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
[PMID: 32305784]
MIA PaCa-2 IC50
17 nM
Compound: PD325901
Antiproliferative activity against human MIAPaCa2 cells
Antiproliferative activity against human MIAPaCa2 cells
[PMID: 23474388]
Sf21 IC50
>25 μM
Compound: PD-0325901
Inhibition of human COT (66 to 395 residues) expressed in Sf21 cells using 5-Fluo-Ahx-AGAGSGQLIDSNleANSFVGTR-NH2 as substrate after 60 mins by caliper microfluidic mobility shift assay
Inhibition of human COT (66 to 395 residues) expressed in Sf21 cells using 5-Fluo-Ahx-AGAGSGQLIDSNleANSFVGTR-NH2 as substrate after 60 mins by caliper microfluidic mobility shift assay
[PMID: 27502541]
SK-MEL-28 GI50
2.9 nM
Compound: 4; PD0325901
Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell growth after 3 days by MTT assay
Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell growth after 3 days by MTT assay
[PMID: 31730343]
SU-DHL-1 GI50
350 nM
Compound: 1; PD0325901
Antiproliferative activity against human SU-DHL-1 cells incubated for 3 days by WST8 assay
Antiproliferative activity against human SU-DHL-1 cells incubated for 3 days by WST8 assay
[PMID: 33284613]
UACC-257 GI50
0.2 nM
Compound: 4; PD0325901
Antiproliferative activity against human UACC257 cells assessed as reduction in cell growth after 3 days by MTT assay
Antiproliferative activity against human UACC257 cells assessed as reduction in cell growth after 3 days by MTT assay
[PMID: 31730343]
体外実験

Mirdametinib (250 nM; 7 d) induces differentiation of cardiac PCs into vascular smooth muscle cell (VSMC)-like cells[1].
Mirdametinib (10 μM; 4 d) induces oligodendrocyte precursor cells (OPC) to oligodendrocytes (OL) differentiation[2].
Mirdametinib enhances embryonic stem cells (ESC) self-renewal capacity both by key regulatory genes and ES cell-specific miRNA, which in turn influences ESC self-renewal and cellular differentiation[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

482.19

分子式

C16H14F3IN2O4

CAS 番号
Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC=C(C(F)=C1NC2=CC=C(I)C=C2F)F)NOC[C@H](O)CO

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション
参考文献
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます:C1V1 = C2V2

濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

 

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Mirdametinib
製品番号:
HY-10254G
数量:
MCE 日本正規代理店: